Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR; DAIS Group. Vakkilainen J, et al. Among authors: taskinen mr. Circulation. 2003 Apr 8;107(13):1733-7. doi: 10.1161/01.CIR.0000057982.50167.6E. Epub 2003 Mar 24. Circulation. 2003. PMID: 12665498 Clinical Trial.
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.
Talmud PJ, Martin S, Steiner G, Flavell DM, Whitehouse DB, Nagl S, Jackson R, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Humphries SE, Syvänne M; Diabetes Atherosclerosis Intervention Study Investigators. Talmud PJ, et al. Among authors: taskinen mr. Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):644-9. doi: 10.1161/01.ATV.0000065196.61663.8D. Epub 2003 Mar 6. Arterioscler Thromb Vasc Biol. 2003. PMID: 12692006 Clinical Trial.
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Keech A, et al. Among authors: taskinen mr. Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2. Lancet. 2005. PMID: 16310551 Clinical Trial.
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Scott R, et al. Among authors: taskinen mr. Diabetes Care. 2009 Mar;32(3):493-8. doi: 10.2337/dc08-1543. Epub 2008 Nov 4. Diabetes Care. 2009. PMID: 18984774 Free PMC article. Clinical Trial.
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung WT, Scott RS, Taskinen MR, Keech AC, Rye KA. Ong KL, et al. Among authors: taskinen mr. Diabetologia. 2015 Mar;58(3):464-73. doi: 10.1007/s00125-014-3458-7. Epub 2014 Nov 26. Diabetologia. 2015. PMID: 25425220 Clinical Trial.
Serum lipids and the progression of nephropathy in type 1 diabetes.
Thomas MC, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, Forsblom C, Cooper ME, Taskinen MR, Viberti G, Groop PH. Thomas MC, et al. Among authors: taskinen mr. Diabetes Care. 2006 Feb;29(2):317-22. doi: 10.2337/diacare.29.02.06.dc05-0809. Diabetes Care. 2006. PMID: 16443880 Free article.
595 results